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A novel autophagy enhancer as a therapeutic agent
against metabolic syndrome and diabetes
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Autophagy is a critical regulator of cellular homeostasis, dysregulation of which is associated
with diverse diseases. Here we show therapeutic effects of a novel autophagy enhancer
identiﬁed by high-throughput screening of a chemical library against metabolic syndrome. An
autophagy enhancer increases LC3-I to LC3-II conversion without mTOR inhibition. MSL, an
autophagy enhancer, activates calcineurin, and induces dephosphorylation/nuclear translo-
cation of transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and
autophagy gene expression. MSL accelerates intracellular lipid clearance, which is reversed
by lalistat 2 or Tfeb knockout. Its administration improves the metabolic proﬁle of ob/ob mice
and ameliorates inﬂammasome activation. A chemically modiﬁed MSL with increased
microsomal stability improves the glucose proﬁle not only of ob/obmice but also of mice with
diet-induced obesity. Our data indicate that our novel autophagy enhancer could be a new
drug candidate for diabetes or metabolic syndrome with lipid overload.
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Macro-autophagy is a cellular process involving lysosomaldegradation of the cell’s own material through forma-tion of a new structure with double membranes
(autophagosome) and its fusion to lysosome (autophagolyso-
some)1. The physiological roles of autophagy include quality
control of organelles or cellular proteins and protection of
nutrient balance2. Because autophagy is critical for the main-
tenance of cellular metabolic homeostasis, it plays a crucial role in
the control of whole-body metabolism, dysregulation of which
may participate in the development of metabolic disorders.
The in vivo role of autophagy in metabolic disorders has been
widely studied using genetic models that showed diverse meta-
bolic features3. For example, mice with knockout of Atg7, an
essential autophagy gene in pancreatic β-cells producing insulin,
showed structural and functional defects of pancreatic β-cells,
resulting in glucose intolerance and susceptibility to diabetes in
the presence of metabolic stress4–6. In contrast, autophagy
knockout in skeletal muscle cells led to the induction of ﬁbroblast
growth factor 21 (FGF21) as a “mitokine” due to mitochondrial
stress and resistance to diet-induced obesity and insulin resis-
tance7, in contrast to the expectation that autophagy deﬁciency
associated with mitochondrial dysfunction in insulin target tis-
sues would lead to insulin resistance. While these genetic models
showed diverse metabolic phenotypes depending on the location
and severity of autophagy deﬁciency, systemic autophagy insuf-
ﬁciency of physiologically relevant degree rather than tissue-
speciﬁc knockout compromised adaptation to metabolic stress
and facilitated progression from obesity to diabetes8. Further-
more, overexpression of Atg5, another essential autophagy gene,
improved the metabolic proﬁle of aged mice9. These results
suggest that systemically enhanced autophagic activity may have
beneﬁcial effects on body metabolism during metabolic stress.
Since autophagy is involved in various biological processes and
diseases, searches for autophagy modulators have been conducted
to develop novel compounds with therapeutic effects against
neurodegeneration, cancer or aging10–13. We screened a chemical
library using a luciferase-based high-throughput assay of autop-
hagic ﬂux14, rather than autophagy level, and identiﬁed novel
small-molecule autophagy enhancers that can improve the
metabolic proﬁle through upregulation of lysosomal function.
Results
Screening of autophagy enhancer small molecules. To screen
autophagy enhancers, we stably transfected HepG2 cells with
wild-type (WT) pRLuc(C124A)-LC3 or a mutant with G120A
substitution that is resistant to proteolytic cleavage and inhibits
LC3-II formation [pRLuc(C124A)-LC3(G120A)]14. We treated
transfectants with a chemical library comprising 7520 compounds
(Korea Chemical Bank) for 24 h and selected 35 chemicals that
reduced normalized the wild/mutant luciferase ratio to <0.6 at 50
μM concentration, due to autophagic degradation of Renilla
luciferase without cytotoxic activity (viability of ≥80% determined
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay) (Supplementary Fig. 1a–c). A normalized
wild/mutant luciferase ratio of 0.6 was chosen since 250 nM
rapamycin, a positive control, reduced the ratio to 0.6. To conﬁrm
enhanced autophagic activity, we conducted Western blot ana-
lysis. Sixteen of 35 chemicals increased LC3-I to LC3-II conver-
sion in the presence of baﬁlomycin A1 (Supplementary Fig. 1a,
d), indicating that they are authentic autophagy enhancers. We
next conducted Western blot analysis using anti-phospho-S6K1
and -phospho-mTOR antibodies to eliminate mTORC1 inhibi-
tors that may exert deleterious effects on the metabolic proﬁle and
pancreatic β-cell function15,16, and identiﬁed seven chemicals that
did not inhibit mTORC1 (Supplementary Fig. 1e). Among them,
three chemicals (#6, #9 and # 30) improved the glucose proﬁle of
ob/ob mice after in vivo administration for 8 weeks in our pre-
liminary experiments (Supplementary Fig. 2). We then selected
one chemical (#9, hereafter called “MSL”) for further in-depth
experiments (Fig. 1a).
Calcineurin activation by MSL enhanced autophagic ﬂux. We
investigated the molecular mechanism of mTORC1-independent
autophagy activation by MSL. Confocal microscopy after mRFP-
GFP-LC3 transfection showed that MSL treatment induced the
formation of red puncta representing the autophagolysosome,
suggesting autophagy progression to the lysosomal step17
(Fig. 1b). When we examined the lysosomal steps of autophagy
more closely employing acridine orange (AO) staining, the
number of acidic vesicles with red ﬂuorescence was signiﬁcantly
increased by MSL treatment for 24 h (Fig. 1c), suggesting
increased lysosomal content18. We therefore studied transcription
factor EB (TFEB), a master regulator of lysosome biogenesis and
autophagy gene expression19. Confocal microscopy showed TFEB
nuclear translocation in >80% of cells treated with 50 μMMSL for
2 h (Fig. 1d). TFEB nuclear translocation was dose-dependent at
MSL concentrations between 1–100 μM (Supplementary Fig. 3a).
Western blot analysis showed increased TFEB mobility in cells
treated with MSL, suggesting TFEB dephosphorylation20
(Fig. 1e). Indeed, Western blot analysis using anti-phospho-S142-
TFEB antibody conﬁrmed reduced TFEB phosphorylation at
S142, an important site of TFEB phosphorylation19, by MSL
treatment for 4 h (Fig. 1e). Furthermore, transfection of cells with
a phosphomimetic Tfeb mutant [Tfeb(S142D)] markedly reduced
nuclear translocation of TFEB by MSL treatment (Fig. 1f), sug-
gesting a crucial role of S142 in TFEB localization by MSL
treatment. To corroborate the role of TFEB nuclear translocation
in autophagy activation, we treated CRISPR/Cas9 Tfeb knockout
HeLa cells21 with MSL. LC3-I to LC3-II conversion after 4 h of
treatment was markedly reduced in Tfeb knockout cells (Fig. 1g),
conﬁrming an essential role of TFEB in autophagy activation by
MSL.
We investigated the mechanism of MSL-induced TFEB
dephosphorylation that is unrelated to the inhibition of
mTORC1, a well-known inducer of TFEB phosphorylation22.
Speciﬁcally, we studied the lysosomal Ca2+-calcineurin pathway
that induces TFEB dephosphorylation23. To determine whether
MSL modulates lysosomal Ca2+ release, HeLa cells were
transfected with GCaMP3-ML1 encoding a lysosome-speciﬁc
Ca2+ probe23. MSL did not induce lysosomal Ca2+ release,
whereas a lysosomotropic agent (Gly-Phe β-naphthylamide,
GPN) or ionomycin did (Fig. 2a). We therefore examined
whether MSL increases calcineurin activity without inducing
lysosomal Ca2+ efﬂux. Calcineurin phosphatase activity was
indeed signiﬁcantly increased by MSL (Fig. 2b). The increase of
calcineurin activity was dose-dependent at MSL concentrations
between 1 and 100 μM (Supplementary Fig. 3b). Furthermore,
MSL-induced calcineurin activation was suppressed by a
combination of cyclosporin A (CsA)+ FK506, calcineurin
inhibitors (Fig. 2b), indicating that MSL increases calcineurin
activity. Pretreatment with CsA+ FK506 combination also
abrogated TFEB translocation after MSL treatment for 4 h
(Fig. 2c), supporting the role of calcineurin activation in TFEB
translocation by MSL. To further conﬁrm the role of calcineurin
in MSL-induced TFEB translocation, we transfected Tfeb-GFP-
transfectants with a dominant-negative mutant of catalytic
calcineurin A subunit (HA-ΔCnA-H151Q)24. MSL-induced
nuclear translocation of TFEB was markedly reduced in
transfected cells (Fig. 2d), suggesting that calcineurin activation
is crucial in nuclear translocation of TFEB by MSL. In contrast,
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transfection of constitutively active calcineurin mutant (HA-
ΔCnA) together with regulatory calcineurin B subunit (CnB)24
induced TFEB nuclear translocation without MSL treatment
(Fig. 2d). Transfection of HA-ΔCaN and CnB also increased LC3-
I to LC3-II conversion in the presence of baﬁlomycin A1,
indicating enhanced autophagic ﬂux (Supplementary Fig. 3c). To
investigate the mechanism of calcineurin activation by MSL, we
studied the physical interaction between MSL and calcineurin A
employing a drug afﬁnity responsive target stability (DARTS)
assay25. When cell lysate was treated with pronase, calcineurin A
stability was markedly decreased. Degradation by pronase was
abrogated by pretreatment with a saturating dose of MSL (1 mM),
suggesting that MSL directly binds to calcineurin A and stabilizes
calcineurin A (Fig. 2e). Nonsaturating dose of MSL (100 μM) did
not protect calcineurin A from degradation by pronase
(Supplementary Fig. 4), probably because maximal protection of
the target protein from proteolysis may require saturation of the
protein with ligand25,26 and treatment of highly concentrated cell
lysate with nonsaturating dose would not be enough for full
protection of target proteins in DARTS assay.
Accelerated clearance of intracellular lipid by MSL. We next
studied whether MSL can improve the cell’s ability to handle
metabolic stress through autophagy. When HeLa cells were loa-
ded with palmitic acid (PA)+ oleic acid (OA) combination for
24 h and then treated with MSL, BODIPY+ lipid accumulation
was markedly reduced after 16 h of treatment (Fig. 3a), showing
increased lipid clearance by MSL. We conﬁrmed the expression of
ATGL and HSL in HeLa cells (data not shown). BODIPY colo-
calized with transfected mRFP-LC3 or LAMP1 in cells treated
with MSL for 1 h (Fig. 3b), suggesting direct interaction between
lipid and autophagolysosome or occurrence of lipophagy. After
24 h of treatment, colocalization between BODIPY and LAMP1
was virtually absent, except a few droplets (Supplementary
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Fig. 1 Identiﬁcation of an autophagy enhancer small-molecule (MSL) inducing nuclear translocation of TFEB. a Chemical structure of autophagy enhancer,
MSL [4-(4-ﬂuorophenyl)sulfonyl-5-methylthio-2-phenyloxazole]. b HeLa cells transfected with mRFP-GFP-LC3 were treated with MSL, and confocal
microscopy was performed. Red puncta represents autophagolysosome (upper). The numbers of yellow and red punctae representing autophagosomes
and autophagolysosomes, respectively, were counted (t= 4.9, df= 6 for autophagosome; t= 10.3, df= 6 for autophagolysosome) (lower). c MSL-treated
cells were stained with AO, and confocal microscopy was performed (upper). The number of acidic AO vesicles was counted (t= 10.3, df= 4) (lower). d
Tfeb-GFP-transfectants were treated with MSL, and then subjected to confocal microscopy to examine nuclear translocation of TFEB (upper). The number
of cells with nuclear TFEB was counted (t= 10.9, df= 4) (lower). e WT and Tfeb knockout HeLa cells were treated with MSL, and cell extract was
subjected to Western blot analysis using the indicated antibodies. Red arrow indicates phospho-S142-TFEB band. Numbers below phospho-S142-TFEB
immunoblot bands indicate fold changes normalized to total TFEB bands. f HeLa cells transfected with 3xFLAG-Tfeb(WT) or -Tfeb(S142D) mutant were
treated with MSL. Confocal microscopy was conducted after immunostaining with anti-FLAG antibody. Arrows indicate cells with nuclear translocation of
TFEB (left panel). The number of cells with nuclear TFEB among FLAG+ cells was counted (F= 51.7, df treatment= 3, df residual= 6) (right). g WT and
Tfeb knockout HeLa cells were treated with MSL in the presence or absence of baﬁlomycin A1 (BafA), and cell extract was subjected to Western blot
analysis using the indicated antibodies. Numbers below LC3 immunoblot bands indicate fold changes of LC3-II normalized to β-actin bands. All data in this
ﬁgure are the means ± s.e.m. from ≥3 independent experiments performed in triplicate (scale bar, 20 μm). **P < 0.01 and ***P < 0.001 by one-way ANOVA
with Tukey’s post-hoc test (f) and two-tailed Student’s t-test (b–d)
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Fig. 5a). The decrease of lipid content by MSL treatment was
largely reversed by orlistat, a nonspeciﬁc lipase inhibitor, or
lalistat 2 (kindly provided by Paul Helquist, University of Notre
Dame, Notre Dame, IN), a speciﬁc lysosomal lipase inhibitor
(Fig. 3a and Supplementary Fig. 5b), suggesting the role of
lysosomal lipolysis in MSL-induced lipid clearance. Lipid clear-
ance by MSL was also reduced by calcineurin inhibitors or baﬁ-
lomycin A1 and in Tfeb or Atg7 knockout cells (Fig. 3c, d and
Supplementary Fig. 5b, c), demonstrating the role of calcineurin-
mediated TFEB nuclear translocation and autophagolysosomal
activity in this process. While MSL expedited lipid clearance after
loading of PA+OA, MSL did not inhibit Hepa1c1c7 cell death
by treatment with PA alone without OA, a condition that does
not induce lipid droplet (LD) formation27 (Supplementary
Fig. 5d), suggesting that MSL acts by inducing degradation of LD
but does not directly inhibit PA-induced lipotoxicity. OA pro-
tected PA-induced cell death (Supplementary Fig. 5d), as pre-
viously reported27.
NACHT, LRR, and PYD domains-containing protein 3
(NLRP3) inﬂammasome activation by lipid is a cause of
metabolic inﬂammation and insulin resistance in obesity28. Since
inﬂammasome activation by lipid is regulated by autophagy29, we
studied whether MSL can modulate inﬂammasome activation.
When the effect of MSL on inﬂammasome activation by PA+
lipopolysaccharide (LPS) combination30 was studied, IL-1β
release from macrophages was signiﬁcantly attenuated (Supple-
mentary Fig. 6a). Furthermore, Western blot analysis showed that
IL-1β maturation, a marker of inﬂammasome activation, was
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Fig. 2 MSL-induced calcineurin activation increases autophagic ﬂux. a HeLa cells transfected with GCaMP3-ML1 encoding a lysosome-speciﬁc Ca2+ probe
were treated with GPN, ionomycin or MSL. Lysosomal Ca2+ release was visualized by confocal microscopy. b Cells were treated with 50 μM MSL with or
without pretreatment with CsA+ FK506 combination (F= 13.4, df treatment= 3, df residual= 6). c Tfeb-GFP-transfectants were treated with MSL with or
without pretreatment with CsA+ FK506 combination, and then subjected to confocal microscopy (upper). The number of cells with nuclear TFEB was
counted (F= 133.5, df treatment= 3, df residual= 11) (lower). d Tfeb-GFP-transfectants were transfected with HA-ΔCnA-H151Q or -ΔCnA construct, and
analyzed by confocal microscopy after treatment with MSL for 4 h and immunostaining with anti-HA antibody (white arrow, HA-ΔCnA-H151Q-transfected
cells showing no TFEB translocation by MSL; red arrows, HA-ΔCnA-H151Q-untransfected cells showing TFEB translocation by MSL; yellow arrows, HA-
ΔCnA-transfected cells showing TFEB translocation without MSL). e Cell lysate was treated with pronase with or without MSL pretreatment, and subjected
to Western blot analysis using anti-calcineurin A antibody. Numbers below immunoblot bands indicate fold changes normalized to β-actin bands (scale
bar, 20 μm). All data in this ﬁgure are the means ± s.e.m. from ≥3 independent experiments performed in triplicate. *P < 0.05, **P < 0.01 and ***P < 0.001
by one-way ANOVA with Tukey’s post-hoc test
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Fig. 3 Decreased intracellular lipid after treatment with autophagy enhancer. a HeLa cells incubated in 2% fatty acid-free BSA-DMEM containing PA (400
μM) and OA (800 μM) for 24 h were treated with MSL in the presence or absence of orlistat. Control cells indicated as (-) were incubated in solvent alone
(2% fatty acid-free BSA-DMEM). After staining with BODIPY493/503, cells were subjected to confocal microscopy to determine the number of lipid
droplets (LDs) (F= 14.3, df treatment= 4, df residual= 8). b HeLa cells loaded with PA+OA combination as in a were treated with MSL. After
immunostaining with anti-LAMP1 antibody and BODIPY493/503 staining, confocal microscopy was conducted (left panel). mRFP-LC3-transfected HeLa
cells were loaded with PA+OA combination as in a and then treated with MSL. After staining with BODIPY493/503, confocal microscopy was conducted
(right panel). c HeLa cells were treated and examined as in a after pretreatment with CsA+ FK506 combination (F= 15.9, df treatment= 4, df residual=
8). dWT or Tfeb knockout HeLa cells were treated and examined as in a (F= 21.3, df treatment= 5, df residual= 10). All data in this ﬁgure are the means
± s.e.m. from ≥3 independent experiments performed in triplicate (scale bar, 20 μm). *P < 0.05 and **P < 0.01 by one-way ANOVA with Tukey’s post-hoc
test
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reduced by MSL, supporting attenuated lipid-induced inﬂamma-
some activation by MSL (Supplementary Fig. 6b). Since
autophagy controls inﬂammasome activation by regulating turn-
over of dysfunctional mitochondria31, we measured mitochon-
drial reactive oxygen species (ROS). MSL signiﬁcantly suppressed
mitochondrial ROS production by treatment with PA+ LPS
combination for 24 h (Supplementary Fig. 6c), indicating
attenuated mitochondrial dysfunction by MSL. Other markers
of mitochondrial dysfunction such as decreased mitochondrial
potential and suppressed ATP-coupled mitochondrial oxygen
consumption after treatment with PA+ LPS combination were
also ameliorated by MSL (Supplementary Fig. 6d, e). During the
study of inﬂammasome activation, we observed that MSL reduced
not only mature IL-1β protein level but also pro-IL-1β protein
level (Supplementary Fig. 6b), which could be due to autophagy-
independent mechanisms. Thus, we determined the mRNA level
of cytokines such as pro-IL-1β, TNFα, and IL-6 that is not
directly affected by inﬂammasome activation. Indeed, mRNA
expression of these cytokines after LPS treatment was signiﬁ-
cantly reduced by MSL (Supplementary Fig. 7a). To study the
mechanism of these ﬁndings, we studied NF-κB activation that
could be reduced by calcineurin through TLR4, MyD88, or TRIF
binding32,33. We observed that IκBα phosphorylation, disappear-
ance of IκBα, p65 phosphorylation and NF-κB reporter activity
induced by LPS were notably attenuated by MSL (Supplementary
Fig. 7b, c), which indicates reduced NF-κB activation by MSL and
suggests that MSL attenuates cytokine release through both
autophagy-dependent and autophagy-independent mechanisms.
Improved metabolic proﬁle of obese mice by MSL. We next
studied whether autophagy enhancement by MSL could improve
the metabolic proﬁle of obese mice in vivo. Administration of 50
mg/kg MSL to ob/ob mice, a genetic mouse model of obesity with
a leptin mutation34, 3 times a week for 8 weeks signiﬁcantly
reduced nonfasting and fasting blood levels (Fig. 4a, b) without
changes in food intake or body weight (Supplementary Fig. 8a, b).
Intraperitoneal glucose tolerance test (IPGTT) and insulin tol-
erance test (ITT) showed signiﬁcantly improved glucose tolerance
and insulin sensitivity, respectively (Fig. 4c, d), with reduced area
under the curves (AUCs) (Supplementary Fig. 8c, d). The glucose
proﬁle of lean mice was not affected by MSL (Fig. 4a–d and
Supplementary Fig. 8c, d). Improved glucose proﬁle after 8 weeks
of MSL administration was accompanied by increased autophagic
ﬂux in the liver of ob/ob mice determined after leupeptin
clamping (Supplementary Fig. 8e). Expression of TFEB-regulated
genes such as Uvrag, Clcn7, Atp6v0e1, and Tfeb itself was sig-
niﬁcantly increased in the liver of MSL-treated mice (Supple-
mentary Fig. 8f), showing enhanced expression of lysosomal
genes and autophagy genes35 after treatment with MSL for
8 weeks.
In the liver, fatty change and triglyceride (TG) accumulation
were reduced by administration of MSL to ob/ob mice for 8 weeks
(Fig. 4e, f). Serum aspartate transaminase (ASL) and alanine
transaminase (ALT) levels were also decreased by MSL treatment
(Fig. 4g), indicating decreased liver damage. In adipose tissue, the
number of crown-like structures (CLSs), a marker of metabolic
inﬂammation, was signiﬁcantly decreased after 8 weeks of MSL
administration (Fig. 4h, i). Real-time RT-PCR demonstrated
signiﬁcantly reduced expression of inﬂammatory genes such as
Tnfα, Il-6, pro-Il-1β, and F4/80 (Fig. 4j), which might be partly
attributable to autophagy-independent mechanisms such as
reduced NF-κB activation. Western blot analysis demonstrated
that MSL treatment attenuated inﬂammasome activation in
adipose tissue of ob/ob mice, as shown by reduced caspase 1
activation and IL-1β maturation (Fig. 4k). We next employed a
diet-induced obesity model which is more physiological com-
pared to ob/ob mouse model. MSL administration for 8 weeks
appeared to reduce nonfasting blood glucose level and glucose
intolerance in mice fed high-fat diet (HFD); however, statistical
signiﬁcance was not achieved for most comparisons except a
certain point during IPGTT (Supplementary Fig. 9a–f).
Metabolic effects of chemically modiﬁed autophagy enhancer.
One of the reasons the metabolic proﬁle of HFD-fed mice was not
signiﬁcantly improved by MSL administration in vivo could be
the poor microsomal stability of MSL (less than 10% remaining
after 30 min incubation with human liver microsome). Thus, we
chemically modiﬁed MSL to make more efﬁcacious and druggable
compounds. Among several derivatives, we selected a chemical
(MSL-7) with improved microsomal stability (90.5% remaining
after 30 min) (Fig. 5a). We conﬁrmed that MSL-7 induced for-
mation of autophagolysosome, TFEB nuclear translocation, and
calcineurin activation in a dose-dependent manner (Fig. 5b, c and
Supplementary Fig. 3a, b). MSL-7 also increased autophagic
activity, reduced TFEB phosphorylation at S142 and bound to
calcineurin A, protecting its degradation by pronase in DARTS
assay, similar to MSL (Supplementary Fig. 3c and Supplementary
Fig. 10a, b). In contrast, MSL derivatives (#9-3 and #9-4) that did
not induce autophagy (data not shown) did not protect calci-
neurin A from degradation by pronase in DARTS assay (Sup-
plementary Fig. 10b), suggesting the importance of calcineurin
binding in autophagy induction by MSL or its derivatives. When
we studied mTOR inhibition to conﬁrm the absence of mTOR
inhibition by MSL-7 employing Western blot analysis, phos-
phorylation of mTOR or S6K1 was not inhibited by MSL-7 or
MSL, while mTOR or S6K1 activation was markedly inhibited by
rapamycin or Torin-1 (Supplementary Fig. 10c). Phosphorylation
of 4EBP1, another target of mTOR, was also not inhibited by
MSL-7 or MSL, while 4EBP1 phosphorylation was markedly
inhibited by Torin-1 but not by rapamycin, consistent with a
previous paper36 (Supplementary Fig. 10c).
Similar to MSL, MSL-7 expedited in vitro clearance of lipid,
which was inhibited by lalistat 2, baﬁlomycin A1, or Atg7 KO
(Supplementary Fig. 5b, c). MSL-7 also attenuated IL-1β release
or inﬂammasome activation by treatment with PA+ LPS in vitro
(Supplementary Fig. 6a, b), again similar to MSL. Mitochondrial
ROS accumulation, reduced mitochondrial potential, and sup-
pressed ATP-coupled mitochondrial oxygen consumption by PA
+ LPS combination were also reversed by MSL-7 (Supplementary
Fig. 6c–e). Furthermore, mRNA levels of pro-IL-1β, TNFα, and
IL-6 after treatment with LPS were signiﬁcantly reduced by MSL-
7 (Supplementary Fig. 7a). IκBα phosphorylation, disappearance
of IκBα, p65 phosphorylation, and NF-κB reporter activity
induced by LPS were also attenuated by MSL-7 (Supplementary
Fig. 7b, c), which suggests that MSL-7 attenuates cytokine release
through both autophagy-dependent and autophagy-independent
mechanisms, similar to MSL.
We next studied the in vivo effect of MSL-7. When
administered to ob/ob mice, MSL-7 signiﬁcantly reduced non-
fasting blood glucose level without changes in body weight
(Fig. 5d, e). IPGTT and ITT demonstrated signiﬁcantly improved
glucose tolerance and insulin sensitivity, respectively, with
reduced AUCs (Fig. 5f–i). When diet-induced obesity model
was employed instead of ob/ob mice, administration of MSL-7 for
8 weeks signiﬁcantly reduced the nonfasting blood glucose level of
HFD-fed mice without changes in body weight (Fig. 6a, b).
IPGTT and ITT also showed signiﬁcantly improved glucose
tolerance and insulin sensitivity, respectively, with reduced AUCs
after MSL-7 treatment of HFD-fed mice (Fig. 6c–f), indicating
that chemically modiﬁed autophagy enhancer can improve the
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Fig. 4 Improved metabolic proﬁle of ob/obmice by administration of autophagy enhancer. a Nonfasting blood glucose level of ob/obmice treated with MSL
(F= 178.3, df= 1). b Fasting blood glucose level after MSL treatment for 8 weeks (F= 8.3, df treatment= 3, df residual= 38). c IPGTT after the same
treatment (F= 49.5, df= 1). d ITT after the same treatment (F= 48.4, df= 1). e Hepatic H&E-stained sections from MSL-treated ob/ob mice. f Hepatic
triglyceride content (t= 3.5, df= 22). g Serum AST/ALT levels (t= 3.7, df= 15 for AST; t= 2.3, df= 15 for ALT). h H&E staining (upper) and
immunohistochemistry using F4/80 antibody (lower) of adipose tissue from ob/ob mice treated with MSL for 8 weeks. i Numbers of CLSs in F4/80
antibody-stained sections (t= 9.4, df= 2). j Expression of cytokines in adipose tissue determined by real-time RT-PCR (t= 6.3, df= 4 for Tnfa; t= 6.5,
df= 4 for Il-6; t= 11.4, df= 4 for Il-1β; t= 5.5, df= 4 for F4/80). k Inﬂammasome activation in adipose tissue examined by Western blot analysis. Numbers
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means ± s.e.m. from ≥3 independent experiments performed in triplicate (scale bar, 100 μm). *P < 0.05, **P < 0.01 and ***P < 0.001 by two-way ANOVA
with Bonferroni’s post-hoc test (a, c, d), one-way ANOVA with Tukey’s post-hoc test (b) or two-tailed Student’s t-test (f, g, i, j)
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glucose proﬁle not only of ob/ob mice but also of mice with diet-
induced obesity. MSL-7 did not affect the glucose proﬁle of lean
or chow-fed mice (Fig. 5d–i and Fig. 6a–f). Levels of fasting blood
glucose, serum insulin, C-peptide or leptin, and HOMA-IR index
representing insulin resistance that were increased in HFD-fed
mice were signiﬁcantly lowered by MSL-7 administration for
8 weeks (Fig. 6g–k). Serum level of nonesteriﬁed fatty acids
(NEFA) that was increased in HFD-fed mice was also lowered by
MSL-7 administration for 8 weeks, while the difference was not
statistically signiﬁcant (Fig. 6l). In contrast, reduced serum
adiponectin level in HFD-fed mice was increased by MSL-7
administration for 8 weeks (Fig. 6m).
We next studied whether metabolic improvement by in vivo
administration of MSL-7 is associated with TFEB activation. In
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the liver of mice fed HFD, TFEB phosphorylation at S142 was
increased, suggesting impaired TFEB signaling in vivo. Admin-
istration of MSL-7 for 8 weeks signiﬁcantly reduced TFEB
phosphorylation at S142 in the liver of HFD-fed mice
(Supplementary Fig. 11), suggesting enhanced TFEB signaling
by MSL-7 in vivo. We also investigated whether knockdown of
Tfeb eliminates the beneﬁcial effect of MSL-7 in vivo to obtain
genetic evidence that MSL-7 improve the metabolic proﬁle of
obese mice by activating the TFEB pathway. In vivo administra-
tion of 1 mg/kg Tfeb siRNA through the tail vein every 7–10 days
signiﬁcantly reversed MSL-7-induced improvement of glucose
proﬁle in HFD-fed mice without signiﬁcant change of body
weight (Supplementary Fig. 12a, b), indicating that the in vivo
metabolic effect of MSL-7 is through activation of TFEB.
Signiﬁcant Tfeb knockdown by Tfeb siRNA was conﬁrmed
in vitro (Supplementary Fig. 12c) and also in vivo (Supplemen-
tary Fig. 12d), while the in vivo effect was relatively weaker
compared to the in vitro effect because liver tissues were obtained
at the end of the in vivo experiment (i.e., 11 days after the last
Tfeb siRNA injection when the in vivo effect waned). IPGTT and
ITT also showed that in vivo Tfeb knockdown partially reversed
improved glucose tolerance and insulin sensitivity by MSL-7
administration (Supplementary Fig. 12e–h). The expression of
gluconeogenesis genes such as glucose-6-phosphatase, phosphoe-
nolpyruvate carboxykinase (PEPCK), fructose 1,6 bisphosphatase,
or pyruvate carboxylase, which was increased in the liver of HFD-
fed mice, was reduced by MSL-7 (Supplementary Fig. 13),
probably due to improved insulin signaling.
When we studied the expression of TFEB downstream genes
after in vivo administration of MSL-7, the expression of Lc3,
Beclin-1, Lamp1, CtsA, and CtsD was increased or derepressed in
the liver after 8 weeks of MSL-7 administration (Supplementary
Fig. 14a). The expression of Tfeb itself was increased after MSL-7
administration (Supplementary Fig. 14a), consistent with a
previous paper reporting that TFEB induces the expression of
Tfeb itself35. In skeletal muscle, the expression of most Tfeb target
genes was not increased after 8 weeks of MSL-7 administration to
HFD-fed mice (Supplementary Fig. 14b). On the other hand, the
expression of mitochondrial genes such as Mfn1, Mfn2, Nrf-1,
Tfam, CoxI, CoxII, CoxIV, CoxVa, Cox8b, or Dlat was
upregulated by MSL-7 (Supplementary Fig. 14c), which shows
differential regulation of TFEB target genes depending on tissue,
in line with a previous paper37. In epididymal white adipose
tissue (eWAT), the expression of Tfeb and several Tfeb down-
stream genes was enhanced by HFD feeding alone and not further
increased by administration of MSL-7 (Supplementary Fig. 14d),
which may be due to upregulation of lysosomal genes in
adipocytes or adipose tissue macrophages as an adaptation to a
local lipid-rich environment38. However, the number of red
puncta in the eWAT of HFD-fed GFP-RFP-LC3 mice represent-
ing the autophagolysosome was signiﬁcantly increased after MSL-
7 administration (Supplementary Fig. 15), indicating that MSL-7
indeed exerted its effects on adipose tissue. Dissociation of Tfeb
expression and autophagolysosome number could be due to the
defective fusion between autophagosome and lysosome in HFD-
fed mice39 leading to no increase of autophagosome number
despite increased Tfeb expression, which might be resolved after
MSL-7 administration. The expression of autophagy genes and
lysosomal genes in the pancreas was not signiﬁcantly changed by
MSL-7 treatment (Supplementary Fig. 14e).
When the changes in weights of metabolic organs were
examined, weight of the liver was reduced to a small but
signiﬁcant degree after in vivo administration of MSL-7 for
8 weeks probably due to reduced lipid content (Supplementary
Fig. 16a), consistent with previous data showing reduced liver
weight after genetic overexpression of Tfeb in the liver35. In
contrast, epididymal fat weight was increased after in vivo
administration of MSL-7 (Supplementary Fig. 16a), which may be
due to increased adipogenesis by Tfeb activation in adipose
tissue40. The expression of PCG-1α, a master regulator of
mitochondrial biogenesis, appeared to be increased in brown
adipose tissue and subcutaneous white adipose tissue (sWAT)
after MSL-7 administration; however, the expression of
thermogenesis-related genes such as Ucp1, deiodinase2, or Elovl3
was not signiﬁcantly or only marginally increased by MSL-7
administration (Supplementary Fig. 16b, c). The expression of
lipogenesis-related genes such as Pparγ2, Scd1, C/ebpα, C/ebpβ or
Fasn was signiﬁcantly increased after in vivo treatment with MSL-
7 in eWAT but not in sWAT (Supplementary Fig. 16d, e), which
might be related to the increased epididymal fat weight after
MSL-7 treatment. The expression of Angptl4, a lipoprotein lipase
inhibitor, was increased probably as a reactive change to
increased lipogenic gene expression. The expression of Glut4 or
Irs1, which are critical in insulin sensitivity, was not signiﬁcantly
changed by MSL-7 administration (Supplementary Fig. 16d, e).
The size of adipocytes was not signiﬁcantly changed after in vivo
administration of MSL-7 (Supplementary Fig. 16f).
We ﬁnally studied the possible toxicity of autophagy-enhancer
small molecules. Administration of MSL or MSL-7 for 8 weeks
did not affect hemogram or blood chemistry of ob/ob mice except
improved metabolic proﬁle and decreased liver enzyme levels
(Supplementary Table 1). Biopsy of the major organs revealed no
abnormalities except improved fatty liver changes (Supplemen-
tary Fig. 17), supporting no signiﬁcant toxicity and potential
druggability of MSL or MSL-7.
Discussion
We here developed new potential therapeutics that can enhance
autophagic activity and improve the metabolic proﬁle of mice
with metabolic syndrome and obesity. These results are consistent
with previous reports that systemic autophagy deﬁciency aggra-
vated metabolic syndrome8, and that genetic Atg5 overexpression
Fig. 5 Improved metabolic proﬁle after in vivo administration of autophagy enhancer with increased microsomal stability (MSL-7) to ob/ob mice. a
Chemical structure of chemically modiﬁed autophagy enhancer, MSL-7, with increased microsomal stability [2-(2-chlorophenyl)-5-methoxy-4-
(phenylsulfonyl)oxazole]. b HeLa cells transfected with tandem mRFP-GFP-LC3 construct were treated with MSL-7 for 1 h, and were subjected to confocal
microscopy (left panel). The numbers of yellow and red punctae representing autophagosomes and autophagolysosomes, respectively, were counted
(right) (t= 3.5, df= 4 for autophagosome; t= 5.8, df= 4 for autophagolysosome). c TFEB-GFP-transfectant HeLa cells were treated with MSL-7 for 4 h,
and were subjected to confocal microscopy (left panel). The number of cells with nuclear TFEB was counted (right) (t= 5.0, df= 2). d, e Eight-week-old
male ob/obmice or 8-week-old male C57BL/6 mice were treated with 50mg/kg MSL-7 3 times a week for 8 weeks, and nonfasting blood glucose level (d)
and body weight (e) were monitored (F= 40.9, df= 1 for d). f IPGTT was conducted after in vivo administration of MSL-7 for 8 weeks (F= 62.3, df= 1). g
AUC of the IPGTT curve in f (F= 25.3, df treatment= 3, df residual= 27). h ITT was conducted after in vivo administration of MSL-7 for 8 weeks
(F= 50.1, df= 1). i AUC of the ITT curve in h (F= 57.7, df treatment= 3, df residual= 26). All data in this ﬁgure are the means ± s.e.m. from ≥3
independent experiments performed in triplicate (scale bar, 20 μm). *P < 0.05, **P < 0.01 and ***P < 0.001 by one-way ANOVA with Tukey’s post-hoc test
(g, i), two-way ANOVA with Bonferroni’s post-hoc test (d, f, h) or two-tailed Student’s t-test (b, c)
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improved the metabolic proﬁle of aged mice9. Our data are also in
line with a report that cardiac autophagy plays a protective role in
the ischemic cardiac disease of mice with diet-induced obesity41
or that spermidine improved cardiac function and extended the
lifespan of aged mice by enhancing autophagy42. Accordingly, a
couple of autophagy enhancers have been employed against
metabolic syndrome in previous studies8,43. However, they might
not be good candidates for therapeutic agents, as the autophagy-
enhancing activity of trehalose has been questioned in a recent
paper44 and imatinib may have side effects precluding its use in
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Fig. 6 Improved metabolic proﬁle of HFD-fed mice after administration of chemically modiﬁed autophagy enhancer, MSL-7. a, b Eight-week-old male
C57BL/6 mice were fed HFD or normal chow diet (NCD) for 8 weeks, and then treated with 50mg/kg MSL-7 3 times a week for 8 weeks. Nonfasting
blood glucose level (a) and body weight (b) were monitored (F= 56.5, df= 1 for a). c IPGTT was conducted after in vivo administration of MSL-7 for
8 weeks (F= 52.7, df= 1). d AUC of the IPGTT curve in c (F= 4.2, df treatment= 3, df residual= 33). e ITT was conducted after in vivo administration of
MSL-7 for 8 weeks (F= 52.6, df= 1). f AUC of the ITT curve in e (F= 10.3, df treatment= 3, df residual= 33). g–mMetabolic parameters of mice treated
with MSL-7. Fasting blood glucose level (g) and serum levels of insulin (h), C-peptide (j), leptin (k), NEFA (l), and adiponectin (m) were determined.
HOMA-IR was calculated (i). All data in this ﬁgure are the means ± s.e.m. from≥ 3 independent experiments performed in triplicate. *P < 0.05, **P < 0.01
and ***P < 0.001 by two-way ANOVA with Bonferroni’s post-hoc test (a, c, e), one-way ANOVA with Tukey’s post-hoc test (d, f) or two-tailed Student’s t-
test (g–m)
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metabolic syndrome45. Thus, our small-molecule autophagy
enhancers could be novel candidates for therapeutic agents
against metabolic syndrome without adverse effects.
Metabolic improvement by MSL and MSL-7 through calci-
neurin activation and TFEB dephosphorylation is similar to the
effects of adenoviral expression of Tfeb35 or its homolog Tfe346
in vivo. Causality between TFEB activation and metabolic
improvement was conﬁrmed by reversal of metabolic changes
after MSL-7 administration by in vivo knockdown of Tfeb. MSL-7
administration also reversed TFEB S142 phosphorylation in the
liver of HFD-fed mice. Maximum plasma concentrations of MSL
and MSL-7 (Cmax) after 50 mg/kg administration were 0.21 μg/
ml (0.61 μM) and 0.57 μg/ml (1.63 μM), respectively (Song JS
et al., unpublished data). At such concentrations, proportions of
cells with TFEB nuclear translocation would be small (see Sup-
plementary Fig. 3). We hypothesize that such a small degree of
nuclear translocation and S142 dephosphorylation of TFEB may
explain the metabolic effect of MSL or MSL-7 in vivo. While
uncontrolled or excessive TFEB activation for a prolonged period
can be oncogenic47, TFEB activation to an appropriate degree and
duration may be beneﬁcial to host metabolism and nutrient
homeostasis since lysosomal function48 and autophagic or
mitophagic activity49,50 decline markedly with aging. Calcineurin
activation has been reported to directly enhance β-cell function or
muscle endurance capacity51,52. Additionally, calcineurin activa-
tion may improve the metabolic proﬁle by upregulating autop-
hagic activity and preserving organelle function.
It is well established that two key components of type 2 dia-
betes are insulin resistance and β-cell failure. However, molecular
and cellular pathogeneses of type 2 diabetes leading to insulin
resistance and β-cell failure are not clearly delineated28,53–55.
Obesity and lipid overload are major risk factors predisposing to
the development of diabetes. At the organelle level, dysfunction or
stress of endoplasmic reticulum (ER) and mitochondria is an
important etiological component in the development of
diabetes56,57. Autophagy deﬁciency due to aging, lipid, or other
causes49,50,58 can lead to dysfunction of ER or mitochondria2.
Furthermore, autophagy deﬁciency compromises adaptation to
metabolic stress or clearance of accumulated lipid6,8,29. Thus,
autophagy deﬁciency in obesity or aging could, in part, be an
underlying cause of ER or mitochondrial dysfunction associated
with diabetes and metabolic syndrome. Enhancement of autop-
hagic activity might be a novel therapeutic approach against
metabolic disorders by targeting fundamental pathogenesis of
these diseases, which could be different from conventional
modalities of diabetes treatment that address abnormal molecular
or cellular processes emanating from the underlying defects such
as decreased autophagic activity and ensuing organelle
dysfunction.
Methods
Screening of autophagy enhancer. HepG2 cells in a 100-mm culture dish were
stably transfected with 5 μg of pRLuc(C124A)-LC3(WT) or a mutant harboring the
G120A substitution [pRLuc(C124A)-LC3(G120A)] that is resistant to proteolytic
cleavage and inhibits conversion of LC3-I to LC3-II, using 10 μl lipofectamine14.
Stable transfectants were selected by culturing in the presence of 400 μg/ml G418
(Invitrogen), and clones that showed normalized wild/mutant luciferase ratio <0.6
after treatment with 250 nM rapamycin for 6 h were isolated for library screening.
Luciferase assay. After treatment of stable HepG2 transfectants expressing pRLuc
(C124A)-LC3(WT) or pRLuc(C124A)-LC3(G120A) with 50 μM chemicals for 24 h,
cells were lysed in a Passive Lysis Buffer (Promega). After addition of an assay
buffer containing 10 μM coelenterazine (Promega), Renilla luciferase activity was
measured using a microplate luminometer (Berthold Technologies).
Cell culture and drugs treatment. HeLa (Korean Cell Line Bank), stable Tfeb-
GFP-transfected HeLa, CRISPR/Cas9 Tfeb knockout HeLa cells, ΔCnA-transfected
HeLa cells and SK-Hep1 cells (Korean Cell Line Bank) were cultured in DMEM
supplemented with 10% FBS. HeLa cells were employed for study of lipid meta-
bolism because HeLa cells express ATGL and HSL. Hepa1c1c7 (Korean Cell Line
Bank) and HepG2 cells (Korean Cell Line Bank), which are well-characterized
hepatocyte cell lines and have long been employed for metabolic studies, were
grown according to the protocols provided by ATCC. All cells were free of
mycoplasma contamination. All cells were routinely monitored for morphologic or
growth changes to prevent cross contamination or genetic drift. For drug treat-
ment, the following concentrations were used: MSL, 100 μM unless stated other-
wise; MSL-7, 100 μM unless stated otherwise; rapamycin, 250 nM; baﬁlomycin,
100 nM unless stated otherwise; cyclosporin A, 10 μM; and FK506, 5 μM. To study
the effect of autophagy enhancer on translocation and phosphorylation of TFEB or
calcineurin activity, cells were treated with MSL or MSL-7 for 4 h. For lipid loading,
cells were treated with a combination of PA (400 μM)+OA (800 μM) for 24 h. PA
solution was made as previously reported27. Brieﬂy, PA stock solution (50 mM)
was prepared by dissolving in 70% ethanol and heating at 50 °C. OA stock solution
(500 mM) was prepared by dissolving in 100% ethanol. The working solution was
made by diluting PA stock and/or OA stock solution in 2% fatty acid-free BSA-
DMEM. As a control solution, 2% fatty acid-free BSA-DMEM was employed. To
study the clearance of lipid by autophagy enhancer, lipid-loaded cells were treated
with MSL for 16 h. To study colocalization of lipid with autophagosome or lyso-
some marker, lipid-loaded cells treated with MSL for 1 h were employed to observe
LD before disappearance. Pretreatment with calcineurin inhibitors was performed
since 1 h before test treatment. MSL (ChemBridge) and MSL-7 were dissolved in
DMSO to make 10 mM and directly diluted to the ﬁnal concentrations in culture
medium for in vitro experiments. For in vivo administration, MSL and MSL-7 were
dissolved in DMSO to yield a 50 mg/ml stock solution, which was diluted with PBS
to 5 mg/ml before injection. All in vitro experiments were repeated at least three
times.
Cell death assay. When treatment with chemicals was completed, medium was
removed and 0.5 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) added. After incubation at 37 °C for 2 h in a CO2 incubator and a
brief centrifugation, supernatant was carefully removed. DMSO was then added to
dissolve insoluble crystals completely, followed by measuring absorbance at 540 nm
using Thermomax microplate reader (Molecular Devices)59. Lipotoxicity was
determined by measuring lactate dehydrogenase release from damaged cells using a
kit (Promega).
Transfection and plasmids. Cells were transiently transfected with plasmids such
as 3xFlag-Tfeb, -Tfeb(S142D), tandem mRFP-GFP-LC3, mRFP-LC3, GCaMP3-
ML1, HA-ΔCnA, or -ΔCnA-H151Q using lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol. When HA-ΔCnA was employed, the
same dose of regulatory calcineurin B subunit (CnB) was transfected together24.
Imaging and image quantiﬁcation. Imaging was conducted using an LSM780
confocal microscope (Zeiss). Counting of the numbers of acidic vesicle, autophagic
puncta, and LD was performed using ImageJ. To visualize LD, HeLa cells were
stained with 20 μg/ml BODIPY493/503 (Invitrogen) for 20 min. To observe acidic
vesicular organelles, HeLa cells were treated with autophagy enhancer for 24 h and
then stained with 5 μg/ml AO (Invitrogen) for 10 min.
Antibodies and Western blot analysis. Cells or tissues were solubilized in a lysis
buffer containing protease inhibitors. Protein concentration was determined using
the Bradford method. Samples (10–30 μg) were separated on 4–12% Bis–Tris gel
(NUPAGE, Invitrogen) or 8–15% SDS-PAGE gel, and transferred to PVDF or
nitrocellulose membranes for Western blot analysis using the ECL method (Pierce).
Antibodies against the following proteins were used: LC3 (Novus NB100–2331,
1:1,000), p62 (Progen GP62-C, 1:1,000), β-actin (Santa Cruz sc47778, 1:5,000),
FLAG (Sigma-Aldrich F3165, 1:2,000), HA (Cell Signaling #2367, 1:1,000), S6K1
(Cell Signaling #9202, 1:1,000), phospho-S6K1 (Cell Signaling #9206, 1:1,000),
mTOR (Cell Signaling #2983, 1:1,000), phospho-mTOR (Cell Signaling #2971,
1:1,000), phospho-4EBP1 (Cell Signaling #2855, 1:1,000), 4EBP1 (Cell Signaling
#9644, 1:1,000), TFEB (Bethyl Laboratories A303-673A, 1:1,000), phospho-S142-
TFEB (Millipore ABE1971, 1:1,000), LAMP1 (Abcam ab24170, 1:250), caspase 1
(Santa Cruz sc514, 1:1,000), IL-1β (Santa Cruz sc7884, 1:1,000), phospho-IκBα
(Santa Cruz sc9246, 1:1,000), IκBα (Santa Cruz sc307, 1:1,000), phospho-p65 (Cell
Signaling #3033, 1:1,000), or p65 (Cell Signaling #8242, 1:1,000). Densitometry of
the protein bands was performed using ImageJ. Images of original Western blotting
are shown in Supplementary Fig. 18.
RNA extraction and real-time RT-PCR. Total RNA was extracted from cells or
tissues using TRIzol (Invitrogen), and cDNA was synthesized using MMLV
Reverse Transcriptase (Promega) according to the manufacturer’s protocol. Real-
time RT-PCR was performed using SYBR green (Takara) in ABI PRISM 7000
(Applied Biosystems). All expression values were normalized to S18 mRNA level.
Primer sequences are listed in Supplementary Table 2.
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GCaMP3 Ca2+ imaging. HeLa cells were grown on 15mm coverslips and trans-
fected with a plasmid encoding a perilysosomal GCaMP3-ML1 Ca2+ probe. After
48 h, lysosomal Ca2+ release was measured in a basal Ca2+ solution containing
145 mM NaCl, 5 mM KCl, 3 mM MgCl2, 10 mM glucose, 1 mM EGTA and 20 mM
HEPES (pH 7.4) with or without MSL, by monitoring ﬂuorescence intensity at 470
nm with a LSM780 confocal microscope (Zeiss). GPN (200 μM) was used as a
positive control for induction of Ca2+ release from lysosome. Ionomycin (1 μM), a
calcium ionophore, was employed to induce a maximal Ca2+ response.
Calcineurin phosphatase activity. The phosphatase activity of calcineurin was
determined using a calcineurin phosphatase activity assay kit (Abcam), according
to the manufacturer’s protocol.
ELISA. Primary peritoneal macrophages were isolated from C57BL/6 mice using
3.85% thioglycollate solution, and treated with 400 μM PA and/or 100 ng/ml LPS.
After incubation for 24 h, IL-1β content in culture supernatants was determined
using a mouse ELISA kit (R&D Systems).
Mitochondrial changes. To determine mitochondrial potential, peritoneal mac-
rophages were stained with 1 μM each of MitoTracker Green and MitoTracker Red
(Invitrogen) at 37 °C for 25 min. Cells were suspended in PBS-1% FBS for analysis
on a FACSVerse (BD Biosciences) using the FlowJo software (TreeStar). To
measure mitochondrial ROS content, cells were incubated with 5 μM MitoSox
(Invitrogen) at 37 °C for 5 min, and FACS analysis was performed. Mitochondrial
oxygen consumption rate (OCR) was measured using XF24 analyzer (Seahorse
Bioscience). Peritoneal macrophages were seeded onto XF24 well plates at a density
of 1 × 106 cells/well and treated with 100 ng/ml LPS and/or 200 μM PA as indicated
in the text. After 24 h of incubation, cells were washed and placed in XF medium.
OCR was measured under basal conditions and after addition of 1 μM oligomycin
to calculate ATP-coupled oxygen consumption.
Animals. Eight-week-old male ob/ob mice (Jackson Laboratory) were maintained
in a 12-h light/12-h dark cycle and fed a chow diet. Fifty mg/kg MSL, MSL-7, or
vehicle was administered intraperitoneally to 8-week-old male ob/ob mice 3 times a
week for 8 weeks. During the observation period, mice were monitored for glucose
proﬁle and weighed. In experiments using diet-induced obesity models, 8-week-old
male C57BL/6 mice were fed HFD for 8 weeks, and then treated with 50 mg/kg
MSL or MSL-7 3 times a week for 8 weeks together with HFD feeding. Plasma
concentrations of MSL or MSL-7 after in vivo administration were determined by
LC-MS/MS. For in vivo clamping of the lysosomal steps of autophagy, 30 mg/kg
leupeptin (Sigma) was administered through tail vein. CAG-RFP-EGFP-LC3-
transgenic mice (Jackson Laboratory) were fed HFD for 8 weeks, and then treated
with 50 mg/kg MSL-7 3 times a week for 8 weeks together with HFD feeding.
Tissue sections prepared as described60 were subjected to ﬂuorescent microscopy
after DAPI staining to identify RFP and GFP puncta. Sample size of mouse
experiments was chosen based on previous in vivo data using ob/ob mice or HFD-
fed mice with α error of 0.05, β error of 0.2, and effect size of 0.25. Mice showing
nonfasting blood glucose level above 500 mg/dl before in vivo experiment or
apparently abnormal sick mice were excluded from the study. Mice experiments
were not randomized and conducted without employing the blinding technique
All animal experiments were conducted in accordance with the Public Health
Service Policy in Humane Care and Use of Laboratory Animals. Mouse
experiments were approved by the IACUC of the Department of Laboratory
Animal Resources of Yonsei University College of Medicine, an AAALAC-
accredited unit. The number of mice used is shown in each ﬁgure.
Glucose tolerance test and insulin tolerance test. IPGTT was performed by
intraperitoneal injection of 1 g/kg glucose after overnight fasting. Blood glucose
concentrations were determined using an One Touch glucometer (Lifescan) before
(0 min) and 15, 30, 60, 120, and 180 min after glucose injection. ITT was conducted
by injecting 0.75 U/kg of regular insulin intraperitoneally to fasted mice and
measuring blood glucose levels at 0, 15, 30, 60, and 120 min. HOMA-IR was
calculated using the following formula: (fasting insulin x fasting glucose)/22.5.
Chemical synthesis of MSL. A solution of methyl bromoacetate (10 g, 65.38
mmol) and benzenesulﬁnic acid, sodium salt (12.9 g, 78.4 mmol) in ethanol (200
ml) was reﬂuxed overnight. Excess solvent was removed under reduced pressure.
The mixture was dissolved in dichloromethane (400 ml) and washed with water
(2 × 200 ml) and brine (150 ml). The organic layer was dried over anhydrous
Na2SO4 and concentrated under reduced pressure to give title compound (13.5 g,
96%). The compound was used in the next step without further puriﬁcation.
To a stirred solution of methyl 2-(phenylsulfonyl) acetate (13.5 g, 67.7 mmol)
and 4-acetamidobenzenesulfonyl azide (16.65 g, 69.31 mmol) in acetonitrile (500
ml) at 0 °C, was added triethylamine (7.0 g, 69.3 mmol) dropwise. The reaction
mixture was stirred at room temperature for 24 h. The reaction mixture was ﬁltered
and washed solid with ethyl acetate thoroughly. The ﬁltrate was concentrated in
vacuo. The resulting residue was puriﬁed by column chromatography using ethyl
acetate and n-hexane to give the title compound as a pale yellow solid (15 g, 99%).
To a reﬂuxing solution of 2-chlorobenzonitrile (600 mg, 4.36 mmol) and
rhodium(I1) acetate (38.55 mg, 0.087 mmol) in chloroform (10 ml) was added a
solution of methyl 2-diazo-2-(phenylsulfonyl) acetate (1.15 g, 4.8 mmol) in
chloroform (10 ml). After the addition was ﬁnished, the reaction mixture was
maintained under reﬂux condition for 3 h. Reaction mixture was cooled and
concentrated under reduced pressure. The residue was puriﬁed by column
chromatography to afford title compound as a white solid (1.4 g, 92%). 1H NMR
(300MHz, DMSO-d6): δ 7.99–7.87 (m, 3H), 7.76–7.59 (m, 4H), 7.58–7.44 (m, 2H),
4.25 (s, 3H).
In vivo transfection. Tfeb siRNA (CCAACCUGUCCAAGAAGGA)61 (Sigma) was
administered through tail vein together with Invivofectamine® 3.0 (ThermoFisher)
every 7–10 days for a total of 3 times since in vivo effect of Invivofectamine® 3.0
wanes after 10 days according to the manufacturer’s instruction. Efﬁcacy of Tfeb
siRNA knockdown was evaluated by real-time RT-PCR using mRNA from cells or
liver tissues and speciﬁc primers.
NF-κB reporter assay. NF-κB reporter activity was determined using pELAM-
luciferase NF-κB reporter construct, as previously described62. In short, primary
peritoneal macrophages were co-transfected with 0.2 μg of pELAM-luc and 0.02 μg
of pRL-TK plasmids using Lipofectamine 2000. Twenty-four h later, transfected
cells were treated with 100 ng/ml LPS with or without pretreatment with 100 μM
MSL or MSL-7. After incubation for 6 h and cell lysis in Passive Lysis Buffer
(Promega), reporter gene activities were determined using Dual-Luciferase assay
system (Centro LB 960) and presented as ﬁreﬂy luciferase activity normalized to
Renilla luciferase activity.
Histology and immunohistochemistry. Tissue samples were ﬁxed in 10% buffered
formalin and embedded in parafﬁn. Sections of 5 μm thickness were stained with
H&E for morphometry, or immunostained with F4/80 antibody (Millipore) to
detect macrophage aggregates surrounding adipocytes (CLSs). Adipocyte diameter
was measured per each section using ImageJ.
Blood chemistry and hemogram. Blood chemistry was determined using a Fuji
Dri-Chem analyzer. Hemogram was obtained from heparinized blood using a
Hamevet950 Blood Analyzer (Drew Scientiﬁc).
Stromal vascular fraction (SVF). To isolate SVF, epididymal adipose tissue was
minced to ~2 mm pieces. After digestion in 2 mg/ml type 2 collagenase (Wor-
thington) solution at 37 °C for 45 min, the tissue was centrifuged at 1000g for 8
min. After ﬁltration through a 70 μm mesh and lysis of red blood cells, SVF was
suspended in PBS-2% BSA (Roche)-2 mM EDTA (Cellgro) for further experiments.
Triglyceride measurement. For biochemical measurement of hepatic TG content,
the lipid was extracted from homogenized tissue using chloroform/methanol
mixture (2:1). Lipid residue after evaporation was suspended in 1% Triton X-100 in
100% ethanol, and mixed with Free Glycerol Reagent containing lipase (Sigma).
After incubation at 37 °C for 5 min, absorbance at 540 nm was measured for cal-
culation of TG concentrations using a standard curve.
DARTS assay. HeLa cells were scraped and lysed with 8 M urea lysis buffer. After
centrifugation for 15 min at 10,000g, supernatant was obtained and protein content
was quantiﬁed using Bradford solution. Before drug treatment, protein con-
centration was diluted to 1 mg/ml. Samples were incubated with MSL of excessive
concentration to maximize the interaction at 4 °C for 4 h. Samples were then
treated with pronase (Roche) for 0, 5, 10, 15 min at 25 °C, and then subjected to
Western blot analysis using anti-calcineurin A antibody.
Liver microsomal stability. The reaction mixture consisted of human liver
microsomes (BD Gentest) in 100 mM potassium phosphate buffer (pH 7.4) and 10
μM test chemicals. After preincubation at 37 °C for 5 min, the reaction was initi-
ated by adding NADPH regenerating solution (BD Biosciences). Samples (50 μl)
were collected at 0 and 30 min. The reaction was terminated by adding 450 μl of
ice-cold acetonitrile with imipramine (100 ng/ml, internal standard). After vor-
texing and centrifugation at 4 °C for 5 min at 13,000 rpm, the clear supernatant was
collected, transferred to liquid chromatography (LC) vials, and analyzed by LC-
MS/MS (Agilent 6460) for the quantiﬁcation of the chemicals.
Statistical analysis. All values are expressed as the means ± s.e.m. of ≥3 inde-
pendent experiments performed in triplicate. Two-tailed Student’s t-test was used
to compare values between two groups. One-way ANOVA with Tukey’s test was
used to compare values between multiple groups. Two-way repeated-measures
ANOVA with Bonferroni’s post-hoc test was employed to compare multiple
repeated measurements between groups. Estimation of variation was evaluated by
computing the sample standard deviation and error in each experiment. We did
not observe notable differences in variances between groups or breach of normal
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distribution precluding application of statistical analyses used in this study. P
values <0.05 were considered to represent statistically signiﬁcant differences.
Data availability. All data related to this manuscript and Supplementary Infor-
mation are available from the corresponding author upon reasonable request.
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